Stuart Alan Weinzimer, MD

• Alfonso Galderisi
• Allison E. Gaffey
• Barbara Gulanski
• Cynthia Brandt
• Garrett Ash
• James Dziura
• Jasmine Gujral
• Jennifer Sherr
• Kasia Lipska
• Laura Marie Nally
• Lisa Fucito
• Marcella Nunez-Smith
• Michelle Van Name
• Paulina Rose
• William Tamborlane
• Xinxin (Katie) Zhu

Diabetes Mellitus, Type 1; Endocrinology; Insulin; Insulin Infusion Systems; Pediatrics; Pancreas, Artificial

• Real-World Diabetes Technology: Overcoming Barriers and DisparitiesMesser L, Addala A, Weinzimer S. Real-World Diabetes Technology: Overcoming Barriers and Disparities. Diabetes Technology & Therapeutics 2023, 25: s-176-s-190. PMID: 36802191, DOI: 10.1089/dia.2023.2511.
• Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 DiabetesAsh G, Nally L, Stults-Kolehmainen M, De Los Santos M, Jeon S, Brandt C, Gulanski B, Spanakis E, Baker J, Weinzimer S, Fucito L. Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes. Clinical Journal Of Sport Medicine 2023, 33: 512-520. PMID: 36715983, DOI: 10.1097/jsm.0000000000001078.
• Navigating barriers to affording and obtaining insulin and diabetes suppliesWilcox A, Lipska K, Weinzimer S, Gujral J, Arakaki A, Kerandi L, Nally L. Navigating barriers to affording and obtaining insulin and diabetes supplies. Journal Of Diabetes 2022, 15: 71-75. PMID: 36562281, PMCID: PMC9870729, DOI: 10.1111/1753-0407.13344.
• “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetesHughes A, Chapman K, Bispham J, Dimsits J, Weinzimer S, Wolf W, Heydarian N. “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes. Journal Of Clinical & Translational Endocrinology 2022, 30: 100310. DOI: 10.1016/j.jcte.2022.100310.
• Abstract 13573: Machine Learning to Identify Predictors of Lapses in a Beginners’ Exercise Program for Adults With Type 1 DiabetesDoshi R, Liu J, Jeon S, Businelle M, Hebert E, Nally L, Stults-Kolehmainen M, Fucito L, Weinzimer S, Gerstein M, Ash G, Stults-Kolehmainen M. Abstract 13573: Machine Learning to Identify Predictors of Lapses in a Beginners’ Exercise Program for Adults With Type 1 Diabetes. Circulation 2022, 146: a13573-a13573. DOI: 10.1161/circ.146.suppl_1.13573.
• “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetesHughes A, Chapman K, Bispham J, Dimsits J, Weinzimer S, Wolf W, Heydarian N. “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes. Journal Of Clinical & Translational Endocrinology 2022, 30: 100310. PMID: 36620758, PMCID: PMC9816066, DOI: 10.1016/j.jcte.2022.100310.
• DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump PracticeDoyle EA, Weinzimer SA, Tamborlane W. DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice. The Science Of Diabetes Self-Management And Care 2022, 48: 476-482. PMID: 36129121, DOI: 10.1177/26350106221125699.
• Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical PracticePhillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O’Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews 2022, 44: 254-280. PMID: 36066457, PMCID: PMC9985411, DOI: 10.1210/endrev/bnac022.
• Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young AdultsCommissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.
• A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetesReiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, Weinzimer SA, Fox LA, Cato A, White NH, Tansey M, Aye T, Tamborlane W, Englert K, Lum J, Mazaika P, Foland-Ross L, Marzelli M, Mauras N. A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes. Nature Communications 2022, 13: 4940. PMID: 36042217, PMCID: PMC9427757, DOI: 10.1038/s41467-022-32289-x.
• Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes.Deshpande S, Weinzimer SA, Gibbons K, Nally LM, Weyman K, Carria L, Zgorski M, Laffel LM, Doyle FJ, Dassau E. Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2022, 19322968221116384. PMID: 35971681, DOI: 10.1177/19322968221116384.
• Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop SystemsDovc K, Battelino T, Beck RW, Sibayan J, Bailey RJ, Calhoun P, Turcotte C, Weinzimer S, Schweiger D, Nimri R, Bergenstal RM. Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems. Diabetes Technology & Therapeutics 2022, 24: 848-852. PMID: 35848991, PMCID: PMC9618368, DOI: 10.1089/dia.2022.0153.
• Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parentsHood KK, Garcia‐Willingham N, Hanes S, Tanenbaum ML, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium T. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obesity And Metabolism 2022, 24: 2309-2318. PMID: 35837984, PMCID: PMC9804666, DOI: 10.1111/dom.14815.
• 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 DiabetesWILCOX A, MENCHER S, NALLY L, WEINZIMER S. 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes. Diabetes 2022, 71 DOI: 10.2337/db22-1025-p.
• 619-P: Understanding Parental Influences on T1D Incorporation in Adolescents and Young AdultsCOMMISSARIAT P, VOLKENING L, WEINZIMER S, DASSAU E, LAFFEL L. 619-P: Understanding Parental Influences on T1D Incorporation in Adolescents and Young Adults. Diabetes 2022, 71 DOI: 10.2337/db22-619-p.
• Correction to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and familiesBanerjee I, Raskin J, Arnoux JB, De Leon DD, Weinzimer SA, Hammer M, Kendall DM, Thornton PS. Correction to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families. Orphanet Journal Of Rare Diseases 2022, 17: 205. PMID: 35585549, PMCID: PMC9118786, DOI: 10.1186/s13023-022-02363-0.
• A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670GWeinzimer S, Bailey RJ, Bergenstal RM, Nimri R, Beck RW, Schatz D, Ambler-Osborn L, Schweiger DS, von dem Berge T, Sibayan J, Johnson ML, Calhoun P, Phillip M, Bergenstal R, Phillip M, Criego A, Bergenstal R, Carlson A, Martens T, Beasley S, Johnson M, Whipple D, Hyatt J, Punel A, Grieme A, Thomas L, LaFrance A, Hasledalen C, Laffel L, Isganaitis E, Freiner E, Ambler-Osborn L, Desrochers H, Turcotte C, Naik N, Roethke L, Fisher M, Nimri R, Nevo M, Bello R, Hamou A, Hermon O, Horesh O, Shiovitch Mantzuri G, Drotz I, Yehiel N, Naveh R, Schatz D, Haller M, Albanese-O'Neill A, Sheehan E, Leey J, Smith M, Jacobsen L, Adams J, Hosford J, Whyte L, Battelino T, Dovč K, Bratina N, Šmigoc Schweiger D, Sever U, Gianini A, Murn Berkopec B, Mali B, Weinzimer S, Weyman K, Carria L, Zgorski M, Danne T, Biester T, von dem Berge T, Weiskorn J, Kordonouri O, Biester S, Aschemeier B, Remus K, Pisarek N, Sibayan J, Beck R, Mouse T, Davis J, Bailey R, Hellmann A, Reese N, Calhoun P, Strayer H, Cohen N, Henderson R, Kollman C, Kennedy J, Woodall W, Mahr I, Hood K, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C, Eggerman T. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. Diabetes Technology & Therapeutics 2022, 24: 573-582. PMID: 35363054, PMCID: PMC9353997, DOI: 10.1089/dia.2021.0568.
• Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact modelHinahara J, Weinzimer SA, Bromley ER, Goss TF, Kendall DM, Hammer M. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal Of Managed Care & Specialty Pharmacy 2022, 28: 10.18553/jmcp.2022.28.4.461. PMID: 35332789, PMCID: PMC10373001, DOI: 10.18553/jmcp.2022.28.4.461.
• Real‐World Diabetes Technology: What Do We Have? Who Are We Missing?Messer LH, Weinzimer SA. Real‐World Diabetes Technology: What Do We Have? Who Are We Missing? Diabetes Technology & Therapeutics 2022, 24: s-159-s-172. PMID: 35475693, DOI: 10.1089/dia.2022.2510.
• Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trialWare J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium D, Hovorka R, Acerini C, Thankamony A, Allen J, Boughton C, Dovc K, Dunger D, Ware J, Musolino G, Tauschmann M, Wilinska M, Hayes J, Hartnell S, Slegtenhorst S, Ruan Y, Haydock M, Mangat J, Denvir L, Kanthagnany S, Law J, Randell T, Sachdev P, Saxton M, Coupe A, Stafford S, Ball A, Keeton R, Cresswell R, Crate L, Cripps H, Fazackerley H, Looby L, Navarra H, Saddington C, Smith V, Verhoeven V, Bratt S, Khan N, Moyes L, Sandhu K, West C, Wadwa R, Alonso G, Forlenza G, Slover R, Towers L, Berget C, Coakley A, Escobar E, Jost E, Lange S, Messer L, Thivener K, Campbell F, Yong J, Metcalfe E, Allen M, Ambler S, Waheed S, Exall J, Tulip J, Buckingham B, Ekhlaspour L, Maahs D, Norlander L, Jacobson T, Twon M, Weir C, Leverenz B, Keller J, Davis N, Kumaran A, Trevelyan N, Dewar H, Price G, Crouch G, Ensom R, Haskell L, Lueddeke L, Mauras N, Benson M, Bird K, Englert K, Permuy J, Ponthieux K, Marrero-Hernandez J, DiMeglio L, Ismail H, Jolivette H, Sanchez J, Woerner S, Kirchner M, Mullen M, Tebbe M, Besser R, Basu S, London R, Makaya T, Ryan F, Megson C, Bowen-Morris J, Haest J, Law R, Stamford I, Ghatak A, Deakin M, Phelan K, Thornborough K, Shakeshaft J, Weinzimer S, Cengiz E, Sherr J, Van Name M, Weyman K, Carria L, Steffen A, Zgorski M, Sibayan J, Beck R, Borgman S, Davis J, Rusnak J, Hellman A, Cheng P, Kanapka L, Kollman C, McCarthy C, Chalasani S, Hood K, Hanes S, Viana J, Lanning M, Fox D, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health 2022, 4: e245-e255. PMID: 35272971, DOI: 10.1016/s2589-7500(22)00020-6.
• Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and familiesBanerjee I, Raskin J, Arnoux JB, De Leon DD, Weinzimer SA, Hammer M, Kendall DM, Thornton PS. Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families. Orphanet Journal Of Rare Diseases 2022, 17: 61. PMID: 35183224, PMCID: PMC8858501, DOI: 10.1186/s13023-022-02214-y.
• Technology Utilization in Black Adolescents with Type 1 Diabetes: Exploring the Decision-Making ProcessMencher SR, Weinzimer SA, Nally LM, Van Name M, Nunez-Smith M, Sadler LS. Technology Utilization in Black Adolescents with Type 1 Diabetes: Exploring the Decision-Making Process. Diabetes Technology & Therapeutics 2022, 24: 249-257. PMID: 35085444, DOI: 10.1089/dia.2021.0413.
• Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and PerspectivesHood KK, Laffel LM, Danne T, Nimri R, Weinzimer S, Sibayan J, Bailey RJ, Schatz D, Bratina N, Bello R, Punel A, Calhoun P, Beck RW, Bergenstal RM, Phillip M. Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. Diabetes Technology & Therapeutics 2021, 23: 857-861. PMID: 34270328, PMCID: PMC9009590, DOI: 10.1089/dia.2021.0153.
• Youth and Parent Perspectives on the Acceptability of a Group Physical Activity and Coping Intervention for Adolescents With Type 1 DiabetesDeJonckheere M, Joiner KL, Ash GI, Savoye M, Adams M, Weinzimer SA, Sadler LS, Grey M. Youth and Parent Perspectives on the Acceptability of a Group Physical Activity and Coping Intervention for Adolescents With Type 1 Diabetes. The Science Of Diabetes Self-Management And Care 2021, 47: 367-381. PMID: 34610760, DOI: 10.1177/26350106211040429.
• Establishing a Global Standard for Wearable Devices in Sport and Exercise Medicine: Perspectives from Academic and Industry StakeholdersAsh GI, Stults-Kolehmainen M, Busa MA, Gaffey AE, Angeloudis K, Muniz-Pardos B, Gregory R, Huggins RA, Redeker NS, Weinzimer SA, Grieco LA, Lyden K, Megally E, Vogiatzis I, Scher L, Zhu X, Baker JS, Brandt C, Businelle MS, Fucito LM, Griggs S, Jarrin R, Mortazavi BJ, Prioleau T, Roberts W, Spanakis EK, Nally LM, Debruyne A, Bachl N, Pigozzi F, Halabchi F, Ramagole DA, Janse van Rensburg DC, Wolfarth B, Fossati C, Rozenstoka S, Tanisawa K, Börjesson M, Casajus JA, Gonzalez-Aguero A, Zelenkova I, Swart J, Gursoy G, Meyerson W, Liu J, Greenbaum D, Pitsiladis YP, Gerstein MB. Establishing a Global Standard for Wearable Devices in Sport and Exercise Medicine: Perspectives from Academic and Industry Stakeholders. Sports Medicine 2021, 51: 2237-2250. PMID: 34468950, PMCID: PMC8666971, DOI: 10.1007/s40279-021-01543-5.
• Bayesian structural time series for biomedical sensor data: A flexible modeling framework for evaluating interventionsLiu J, Spakowicz DJ, Ash GI, Hoyd R, Ahluwalia R, Zhang A, Lou S, Lee D, Zhang J, Presley C, Greene A, Stults-Kolehmainen M, Nally LM, Baker JS, Fucito LM, Weinzimer SA, Papachristos AV, Gerstein M. Bayesian structural time series for biomedical sensor data: A flexible modeling framework for evaluating interventions. PLOS Computational Biology 2021, 17: e1009303. PMID: 34424894, PMCID: PMC8412351, DOI: 10.1371/journal.pcbi.1009303.
• Youth and parent preferences for an ideal AP system: It is all about reducing burdenCommissariat PV, Roethke LC, Finnegan JL, Guo Z, Volkening LK, Butler DA, Dassau E, Weinzimer SA, Laffel LM. Youth and parent preferences for an ideal AP system: It is all about reducing burden. Pediatric Diabetes 2021, 22: 1063-1070. PMID: 34324772, PMCID: PMC8530854, DOI: 10.1111/pedi.13252.
• Evaluation of Web-Based and In-Person Methods to Recruit Adults With Type 1 Diabetes for a Mobile Exercise Intervention: Prospective Observational StudyAsh GI, Griggs S, Nally LM, Stults-Kolehmainen M, Jeon S, Brandt C, Gulanski BI, Spanakis EK, Baker JS, Whittemore R, Weinzimer SA, Fucito LM. Evaluation of Web-Based and In-Person Methods to Recruit Adults With Type 1 Diabetes for a Mobile Exercise Intervention: Prospective Observational Study. JMIR Diabetes 2021, 6: e28309. PMID: 34047700, PMCID: PMC8299346, DOI: 10.2196/28309.
• 49-LB: Navigating Barriers to Affording and Obtaining Diabetes TreatmentWILCOX A, KERANDI L, LIPSKA K, WEINZIMER S, NALLY L. 49-LB: Navigating Barriers to Affording and Obtaining Diabetes Treatment. Diabetes 2021, 70 DOI: 10.2337/db21-49-lb.
• PR3 Identifying Preferences for Closed-Loop Insulin Systems Among Children with Type 1 Diabetes and Their Parents: A Discrete Choice ExperimentKelley M, Wadwa P, Buckingham B, Thankamony A, Campbell F, Weinzimer S, Mauras N, DiMeglio L, Denvir L, Davis N, Ghatak A, Besser R, Fox D. PR3 Identifying Preferences for Closed-Loop Insulin Systems Among Children with Type 1 Diabetes and Their Parents: A Discrete Choice Experiment. Value In Health 2021, 24: s196-s197. DOI: 10.1016/j.jval.2021.04.983.
• 214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised TrialFUCHS J, BOUGHTON C, ALLEN J, WILINSKA M, TAUSCHMANN M, DENVIR L, THANKAMONY A, CAMPBELL F, WADWA R, BUCKINGHAM B, DAVIS N, DIMEGLIO L, MAURAS N, BESSER R, GHATAK A, WEINZIMER S, HOOD K, FOX D, KANAPKA L, KOLLMAN C, SIBAYAN J, BECK R, HOVORKA R. 214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised Trial. Diabetes 2021, 70 DOI: 10.2337/db21-214-or.
• 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1DHUGHES A, CHAPMAN K, BISPHAM J, HEYDARIAN N, DIMSITS J, WEINZIMER S, WOLF W. 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D. Diabetes 2021, 70 DOI: 10.2337/db21-51-lb.
• Practical Diabetes Technology: Overcoming Barriers in the Real WorldMesser LH, Weinzimer SA. Practical Diabetes Technology: Overcoming Barriers in the Real World. Diabetes Technology & Therapeutics 2021, 23: s-159-s-168. PMID: 34061638, DOI: 10.1089/dia.2021.2511.
• Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control SystemSchoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD, Gonder-Frederick L, Robic J, Voelmle M, Conschafter K, Morris K, Barnett C, Carr K, Hellmann J, Kime M, Todd Alonso G, Slover R, Berget C, Towers L, Lange S, Buckingham B, Maahs D, Lal R, Ekhlaspour L, Norlander L, Hood K, Town M, Weir C, Smith K, Hsu L, Shinksy D, Viana J, Cengiz E, Weinzimer S, Weyman K, Carria L, Zgorski M, Ruedy K, Beck R, Borgman S, Rusnak J, Kanapka L, Kollman C, Murphy C, Arreza-Rubin G, Green N, Kovatchev B, Brown S, Anderson S, Breton M, Laffel L, Pinsker J, Levy C, Kudva Y, Wadwa R, Buckingham B, Doyle III F, Renard E, Cobelli C, Reznik Y, Arreza-Rubin G, Lum J, Beck R, Ruedy K, Janicek R, Gabrielson D. Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technology & Therapeutics 2021, 23: 475-481. PMID: 33689454, PMCID: PMC8252894, DOI: 10.1089/dia.2020.0646.
• Automated Insulin DeliveryWeinzimer S, Carria L, Van Name M. Automated Insulin Delivery. 2021, 75-85. DOI: 10.1007/978-3-030-64133-7_8.
• Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care 2021, 44: 983-992. PMID: 33568403, PMCID: PMC7985430, DOI: 10.2337/dc20-2125.
• Innovative features and functionalities of an artificial pancreas system: What do youth and parents want?Commissariat PV, Volkening LK, Butler DA, Dassau E, Weinzimer SA, Laffel LM. Innovative features and functionalities of an artificial pancreas system: What do youth and parents want? Diabetic Medicine 2021, 38: e14492. PMID: 33290599, PMCID: PMC9196947, DOI: 10.1111/dme.14492.
• Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer MJ, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, DeBoer MD, Buckingham BA, Oliveri M, Kollman C, Dokken BB, Cherñavvsky D, Beck RW. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care 2021, 44: 473-478. PMID: 33355258, PMCID: PMC7818334, DOI: 10.2337/dc20-1729.
• A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trialBergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O'Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M, Group F. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. The Lancet 2021, 397: 208-219. PMID: 33453783, PMCID: PMC9194961, DOI: 10.1016/s0140-6736(20)32514-9.
• Transformations: What I Learned Along My Patient’s Gender JourneyWeinzimer SA. Transformations: What I Learned Along My Patient’s Gender Journey. Pediatrics 2020, 146: e20200756. PMID: 33028662, DOI: 10.1542/peds.2020-0756.
• Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetesNimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine 2020, 26: 1380-1384. PMID: 32908282, DOI: 10.1038/s41591-020-1045-7.
• A Randomized Trial of Closed-Loop Control in Children with Type 1 DiabetesBreton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. New England Journal Of Medicine 2020, 383: 836-845. PMID: 32846062, PMCID: PMC7920146, DOI: 10.1056/nejmoa2004736.
• Effect of Afrezza on Glucose Dynamics During HCL TreatmentGalderisi A, Cohen N, Calhoun P, Kraemer K, Breton M, Weinzimer S, Cengiz E. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care 2020, 43: 2146-2152. PMID: 32661108, PMCID: PMC7440894, DOI: 10.2337/dc20-0091.
• The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis.Tosur M, Cleves M, Sosenko J, Libman I, Baidal D, Balasubramanyam A, Redondo M, Greenbaum C, Anderson M, Antinozzi P, Atkinson M, Battaglia M, Becker D, Bingley P, Bosi E, Buckner J, Colman P, DiMeglio L, Gitelman S, Goland R, Gottlieb P, Herold K, Insel R, Kay T, Knip M, Krischer J, Lernmark A, Marks J, Moran A, Palmer J, Peakman M, Philipson L, Pugliese A, Raskin P, Redondo M, Rodriguez H, Roep B, Russell W, Spain L, Schatz D, Sosenko J, Wherrett D, Wilson D, Winter W, Ziegler A, Benoist C, Blum J, Bourcier K, Chase P, Clare-Salzler M, Clynes R, Eisenbarth G, Fathman C, Grave G, Hering B, Kaufman F, Leschek E, Mahon J, Nanto-Salonen K, Nepom G, Orban T, Parkman R, Pescovitz M, Peyman J, Roncarolo M, Savage P, Simell O, Sherwin R, Siegelman M, Skyler J, Steck A, Thomas J, Trucco M, Wagner J, Greenbaum C, Bourcier K, Insel R, Krischer J, Leschek E, Rafkin L, Spain L, Cowie C, Foulkes M, Krause-Steinrauf H, Lachin J, Malozowski S, Peyman J, Ridge J, Savage P, Skyler J, Zafonte S, Greenbaum C, Kenyon N, Rafkin L, Santiago I, Sosenko J, Skyler J, Krischer J, Bundy B, Abbondondolo M, Adams T, Amado D, Asif I, Boonstra M, Bundy B, Burroughs C, Cuthbertson D, Deemer M, Eberhard C, Fiske S, Ford J, Garmeson J, Guillette H, Geyer S, Hays B, Henderson C, Henry M, Heyman K, Hsiao B, Karges C, Keaton N, Kinderman A, Law P, Leinbach A, Linton C, Liu S, Lloyd J, Malloy J, Maddox K, Martin J, Miller J, Milliot E, Moore M, Muller S, Nguyen T, O’Donnell R, Oduah V, Pilger J, Roberts A, Sadler K, Stavros T, Tamura R, Wood K, Xu P, Young K, Alies P, Badias F, Baker A, Bassi M, Beam C, Boulware D, Bounmananh L, Bream S, Freeman D, Gough J, Ginem J, Granger M, Kieffer M, Lane P, Nallamshetty L, Parrimon Y, Paulus K, Ramiro J, Ritzie A, Sharma A, Shor A, Song X, Terry A, Weinberger J, Wootten M, Lachin J, Foulkes M, Harding P, Krause-Steinrauf H, McDonough S, McGee P, Hess K, Phoebus D, Quinlan S, Raiden E, Greenbaum C, Batts E, Buddy C, Kirpatrick K, Ramey M, Shultz A, Webb C, Romesco M, Fradkin J, Leschek E, Spain L, Savage P, Blumberg E, Beck G, Brillon D, Gubitosi-Klug R, Laffel L, Veatch R, Wallace D, Braun J, Lernmark A, Lo B, Mitchell H, Naji A, Nerup J, Orchard T, Steffes M, Tsiatis A, Zinman B, Loechelt B, Baden L, Green M, Weinberg A, Marcovina S, Palmer J, Weinberg A, Yu L, Babu S, Winter W, Eisenbarth G, Bingley P, Clynes R, DiMeglio L, Eisenbarth G, Greenbaum C, Hays B, Krischer J, Leschek E, Marks J, Matheson D, Rafkin L, Rodriguez H, Skyler J, Sosenko J, Spain L, Wilson D, Redondo M, Gomez D, Zheng X, Pena S, Pietropaolo M, Greenbaum C, Batts E, Brown T, Buckner J, Dove A, Hammond M, Hefty D, Klein J, Kuhns K, Letlau M, Lord S, McCulloch-Olson M, Miller L, Nepom G, Odegard J, Ramey M, Sachter E, St. Marie M, Stickney K, VanBuecken D, Vellek B, Webber C, Allen L, Bollyk J, Hilderman N, Ismail H, Lamola S, Sanda S, Vendettuoli H, Tridgell D, Monzavi R, Bock M, Fisher L, Halvorson M, Jeandron D, Kim M, Wood J, Geffner M, Kaufman F, Parkman R, Salazar C, Goland R, Clynes R, Cook S, Freeby M, Gallagher M, Gandica R, Greenberg E, Kurland A, Pollak S, Wolk A, Chan M, Koplimae L, Levine E, Smith K, Trast J, DiMeglio L, Blum J, Evans-Molina C, Hufferd R, Jagielo B, Kruse C, Patrick V, Rigby M, Spall M, Swinney K, Terrell J, Christner L, Ford L, Lynch S, Menendez M, Merrill P, Pescovitz M, Rodriguez H, Alleyn C, Baidal D, Fay S, Gaglia J, Resnick B, Szubowicz S, Weir G, Benjamin R, Conboy D, deManbey A, Jackson R, Jalahej H, Orban T, Ricker A, Wolfsdorf J, Zhang H, Wilson D, Aye T, Baker B, Barahona K, Buckingham B, Esrey K, Esrey T, Fathman G, Snyder R, Aneja B, Chatav M, Espinoza O, Frank E, Liu J, Perry J, Pyle R, Rigby A, Riley K, Soto A, Gitelman S, Adi S, Anderson M, Berhel A, Breen K, Fraser K, Gerard-Gonzalez A, Jossan P, Lustig R, Moassesfar S, Mugg A, Ng D, Prahalod P, Rangel-Lugo M, Sanda S, Tarkoff J, Torok C, Wesch R, Aslan I, Buchanan J, Cordier J, Hamilton C, Hawkins L, Ho T, Jain A, Ko K, Lee T, Phelps S, Rosenthal S, Sahakitrungruang T, Stehl L, Taylor L, Wertz M, Wong J, Philipson L, Briars R, Devine N, Littlejohn E, Grant T, Gottlieb P, Klingensmith G, Steck A, Alkanani A, Bautista K, Bedoy R, Blau A, Burke B, Cory L, Dang M, Fitzgerald-Miller L, Fouts A, Gage V, Garg S, Gesauldo P, Gutin R, Hayes C, Hoffman M, Ketchum K, Logsden-Sackett N, Maahs D, Messer L, Meyers L, Michels A, Peacock S, Rewers M, Rodriguez P, Sepulbeda F, Sippl R, Steck A, Taki I, Tran B, Tran T, Wadwa R, Zeitler P, Barker J, Barry S, Birks L, Bomsburger L, Bookert T, Briggs L, Burdick P, Cabrera R, Chase P, Cobry E, Conley A, Cook G, Daniels J, DiDomenico D, Eckert J, Ehler A, Eisenbarth G, Fain P, Fiallo-Scharer R, Frank N, Goettle H, Haarhues M, Harris S, Horton L, Hutton J, Jeffrrey J, Jenison R, Jones K, Kastelic W, King M, Lehr D, Lungaro J, Mason K, Maurer H, Nguyen L, Proto A, Realsen J, Schmitt K, Schwartz M, Skovgaard S, Smith J, Vanderwel B, Voelmle M, Wagner R, Wallace A, Walravens P, Weiner L, Westerhoff B, Westfall E, Widmer K, Wright H, Schatz D, Abraham A, Atkinson M, Cintron M, Clare-Salzler M, Ferguson J, Haller M, Hosford J, Mancini D, Rohrs H, Silverstein J, Thomas J, Winter W, Cole G, Cook R, Coy R, Hicks E, Lewis N, Marks J, Pugliese A, Blaschke C, Matheson D, Pugliese A, Sanders-Branca N, Sosenko J, Arce L, Cisneros M, Sabbag S, Moran A, Gibson C, Fife B, Hering B, Kwong C, Leschyshyn J, Nathan B, Pappenfus B, Street A, Boes M, Eck S, Finney L, Fischer T, Martin A, Muzamhindo C, Rhodes M, Smith J, Wagner J, Wood B, Becker D, Delallo K, Diaz A, Elnyczky B, Libman I, Pasek B, Riley K, Trucco M, Copemen B, Gwynn D, Toledo F, Rodriguez H, Bollepalli S, Diamond F, Eyth E, Henson D, Lenz A, Shulman D, Raskin P, Adhikari S, Dickson B, Dunnigan E, Lingvay I, Pruneda L, Ramos-Roman M, Raskin P, Rhee C, Richard J, Siegelman M, Sturges D, Sumpter K, White P, Alford M, Arthur J, Aviles-Santa M, Cordova E, Davis R, Fernandez S, Fordan S, Hardin T, Jacobs A, Kaloyanova P, Lukacova-Zib I, Mirfakhraee S, Mohan A, Noto H, Smith O, Torres N, Wherrett D, Balmer D, Eisel L, Kovalakovska R, Mehan M, Sultan F, Ahenkorah B, Cevallos J, Razack N, Mary Ricci J, Rhode A, Srikandarajah M, Steger R, Russell W, Black M, Brendle F, Brown A, Moore D, Pittel E, Robertson A, Shannon A, Thomas J, Herold K, Feldman L, Sherwin R, Tamborlane W, Weinzimer S, Toppari J, Kallio T, Kärkkäinen M, Mäntymäki E, Niininen T, Nurmi B, Rajala P, Romo M, Suomenrinne S, Näntö-Salonen K, Simell O, Simell T, Bosi E, Battaglia M, Bianconi E, Bonfanti R, Grogan P, Laurenzi A, Martinenghi S, Meschi F, Pastore M, Falqui L, Muscato M, Viscardi M, Bingley P, Castleden H, Farthing N, Loud S, Matthews C, McGhee J, Morgan A, Pollitt J, Elliot-Jones R, Wheaton C, Knip M, Siljander H, Suomalainen H, Colman P, Healy F, Mesfin S, Redl L, Wentworth J, Willis J, Farley M, Harrison L, Perry C, Williams F. The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. The Journal Of Clinical Endocrinology & Metabolism 2020, 105: e4393-e4406. PMID: 32502242, PMCID: PMC7531906, DOI: 10.1210/clinem/dgaa348.
• 1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) SystemCOMMISSARIAT P, ROETHKE L, FINNEGAN J, VOLKENING L, MCGILL D, DASSAU E, WEINZIMER S, LAFFEL L. 1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) System. Diabetes 2020, 69 DOI: 10.2337/db20-1298-p.
• 8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1DHUGHES A, BISPHAM J, FULLER L, WOLF W, FITCH S, WEINZIMER S. 8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D. Diabetes 2020, 69 DOI: 10.2337/db20-8-lb.
• 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and ParentsROETHKE L, COMMISSARIAT P, FINNEGAN J, VOLKENING L, BUTLER D, DASSAU E, WEINZIMER S, LAFFEL L. 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents. Diabetes 2020, 69 DOI: 10.2337/db20-998-p.
• Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working MemoryFoland-Ross LC, Tong G, Mauras N, Cato A, Aye T, Tansey M, White NH, Weinzimer SA, Englert K, Shen H, Mazaika PK, Reiss AL, Tsalikian E, Tansey M, Coffey J, Cabbage J, Salamat S, Bisbee R, Mauras N, Fox L, Cato A, Englert K, Sikes K, Ewen T, Bird K, Buckingham B, Wilson D, Aye T, Kingman R, Weinzimer S, Tamborlane W, Ambrosino J, Steffen A, Weyman K, Zgorski M, White N, Arbelaez A, Levandoski L, Starnes A, Hershey T, Reiss A, Foland-Ross L, Marzelli M, Mazaika P, Tong G, Sperling M, Becker D, Cleary P, Greenbaum C, Moran A. Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory. Diabetes 2020, 69: 1770-1778. PMID: 32471809, PMCID: PMC7372069, DOI: 10.2337/db20-0123.
• Precision Dosing of Rapid-Acting Insulin MattersAanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technology & Therapeutics 2020, 22: 346-351. PMID: 32125891, DOI: 10.1089/dia.2019.0374.
• Practical Implementation of Diabetes Technology: Real‐World UseMesser LH, Weinzimer SA. Practical Implementation of Diabetes Technology: Real‐World Use. Diabetes Technology & Therapeutics 2020, 22: s-119-s-129. PMID: 32069150, PMCID: PMC7869873, DOI: 10.1089/dia.2020.2509.
• Longitudinal assessment of hippocampus structure in children with type 1 diabetesLC F, AL R, PK M, N M, SA W, T A, MJ T, NH W. Longitudinal assessment of hippocampus structure in children with type 1 diabetes. 2019 DOI: 10.1530/ey.16.10.13.
• Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesDanne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.
• Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeBattelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019, 42: 1593-1603. PMID: 31177185, PMCID: PMC6973648, DOI: 10.2337/dci19-0028.
• 1346-P: Longitudinal Evaluation of Cognitive Functioning in Young Children with Type 1 Diabetes: Persistent Effects on IQ and VocabularyWEINZIMER S, AMBROSINO J, CATO A, JO B, ENGLERT K, WHITE N, ARBELAEZ A, HERSHEY T, FOX L, TSALIKIAN E, TANSEY M, BUCKINGHAM B, AYE T, WILSON D, TAMBORLANE W, REISS A, MAURAS N. 1346-P: Longitudinal Evaluation of Cognitive Functioning in Young Children with Type 1 Diabetes: Persistent Effects on IQ and Vocabulary. Diabetes 2019, 68 DOI: 10.2337/db19-1346-p.
• 1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 DiabetesFOLAND-ROSS L, BUCKINGHAM B, MAURAS N, ARBELAEZ A, WHITE N, AYE T, WILSON D, TAMBORLANE W, WEINZIMER S, TSALIKIAN E, TANSEY M, CATO A, HERSHEY T, FOX L, TONG G, ENGLERT K, MAZAIKA P, REISS A. 1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-1382-p.
• 209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet)ARBELAEZ A, O’DONOGHUE S, MAURAS N, BUCKINGHAM B, WHITE N, WEINZIMER S, AYE T, TSALIKIAN E, WILSON D, TAMBORLANE W, TANSEY M, CATO A, HERSHEY T, FOX L, ENGLERT K, REISS A. 209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet). Diabetes 2019, 68 DOI: 10.2337/db19-209-or.
• 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1DDANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.
• 1361-P: Features to Increase Glycemic Benefits in an Ideal Artificial Pancreas (AP): Perspectives of Young Persons with Type 1 Diabetes (T1D)COMMISSARIAT P, ROETHKE L, FINNEGAN J, VOLKENING L, MCGILL D, DASSAU E, WEINZIMER S, LAFFEL L. 1361-P: Features to Increase Glycemic Benefits in an Ideal Artificial Pancreas (AP): Perspectives of Young Persons with Type 1 Diabetes (T1D). Diabetes 2019, 68 DOI: 10.2337/db19-1361-p.
• 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D)COMMISSARIAT P, ROETHKE L, VOLKENING L, BUTLER D, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D). Diabetes 2019, 68 DOI: 10.2337/db19-816-p.
• 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) SurveyCOMMISSARIAT P, VOLKENING L, ROETHKE L, GUO Z, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey. Diabetes 2019, 68 DOI: 10.2337/db19-817-p.
• Impact of Early Diabetic Ketoacidosis on the Developing BrainAye T, Mazaika PK, Mauras N, Marzelli MJ, Shen H, Hershey T, Cato A, Weinzimer SA, White NH, Tsalikian E, Jo B, Reiss AL, Tsalikian E, Tansey M, Coffey J, Cabbage J, Salamati S, Mauras N, Fox L, Cato A, Englert K, Sikes K, Buckingham B, Wilson D, Aye T, Caswell K, Ambers E, Weinzimer S, Tamborlane W, Steffen A, Weyman K, Zgorski M, Ambrosino J, White N, Arbelaez A, Levandoski L, Starnes A, Hershey T, Reiss A, Barnea-Goraly N, Marzelli M, Mazaika P, Peng D, Beck R, Kollman C, Ruedy K, Winer K, Sperling M, Becker D, Cleary P, Greenbaum C, Moran A. Impact of Early Diabetic Ketoacidosis on the Developing Brain. Diabetes Care 2018, 42: dc181405. PMID: 30573652, PMCID: PMC6385695, DOI: 10.2337/dc18-1405.
• Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes ManagementAdams RN, Tanenbaum ML, Hanes SJ, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. Diabetes Technology & Therapeutics 2018, 20: 648-653. PMID: 30239219, DOI: 10.1089/dia.2018.0174.
• Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes AssociationChiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, Wolfsdorf JI, Schatz D. Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care 2018, 41: dci180023. PMID: 30093549, PMCID: PMC6105320, DOI: 10.2337/dci18-0023.
• Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG TrialForlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018, 41: dc180771. PMID: 30089663, DOI: 10.2337/dc18-0771.
• Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1DPETTUS J, WEINZIMER S, MCCRIMMON R, AMPUDIA BLASCO F, STEWART J, STRUMPH P, OLIVEIRA J, LAPUERTA P, CASTRO R. Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D. Diabetes 2018, 67 DOI: 10.2337/db18-5-lb.
• Exceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG StudyPINSKER J, LI Z, BUCKINGHAM B, FORLENZA G, CENGIZ E, CHURCH M, EKHLASPOUR L, PAUL WADWA R, WEINZIMER S, ANDRE C, MARCAL T, JOST E, CARRIA L, WOODALL W, DOKKEN B, SWANSON V, LUM J, KOLLMAN C, BECK R. Exceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG Study. Diabetes 2018, 67 DOI: 10.2337/db18-86-lb.
• Longitudinal assessment of hippocampus structure in children with type 1 diabetesFoland‐Ross L, Reiss AL, Mazaika PK, Mauras N, Weinzimer SA, Aye T, Tansey MJ, White NH, Network T. Longitudinal assessment of hippocampus structure in children with type 1 diabetes. Pediatric Diabetes 2018, 19: 1116-1123. PMID: 29675980, PMCID: PMC6195484, DOI: 10.1111/pedi.12683.
• Safety and Health Outcomes of a Physical Activity Program for Adolescents with Type 1 DiabetesAsh G, Joiner K, Savoye M, Baker J, Gerosa J, Kleck E, Patel N, Stults-Kolehmainen M, Weinzimer S, Grey M. Safety and Health Outcomes of a Physical Activity Program for Adolescents with Type 1 Diabetes. Medicine & Science In Sports & Exercise 2018, 50: 695. DOI: 10.1249/01.mss.0000538288.29524.c4.
• Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G SystemMesser LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care 2018, 41: dc171682. PMID: 29444895, PMCID: PMC6463622, DOI: 10.2337/dc17-1682.
• An Effective Diabetic Ketoacidosis Prevention Intervention in Children With Type 1 DiabetesVitale RJ, Card CE, Lichtman JH, Weyman K, Michaud C, Sikes K, Tamborlane WV, Weinzimer SA. An Effective Diabetic Ketoacidosis Prevention Intervention in Children With Type 1 Diabetes. SAGE Open Nursing 2018, 4: 2377960818804742. PMID: 33415207, PMCID: PMC7774356, DOI: 10.1177/2377960818804742.
• A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With DiabetesLaffel LM, Aleppo G, Buckingham BA, Forlenza GP, Rasbach LE, Tsalikian E, Weinzimer SA, Harris DR. A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes. Journal Of The Endocrine Society 2017, 1: js.2017-00389-. PMID: 29344578, PMCID: PMC5760209, DOI: 10.1210/js.2017-00389.
• Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D ExchangeAgiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, Kowalski AJ, Madden P, McAuliffe-Fogarty AH, McElwee-Malloy M, Peters A, Raman S, Reifschneider K, Rubin K, Weinzimer SA. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017, 40: 1622-1630. PMID: 29162582, PMCID: PMC5864122, DOI: 10.2337/dc17-1624.
• International Consensus on Use of Continuous Glucose MonitoringDanne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017, 40: 1631-1640. PMID: 29162583, PMCID: PMC6467165, DOI: 10.2337/dc17-1600.
• Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system usersTanenbaum ML, Iturralde E, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users. Journal Of Health Psychology 2017, 25: 429-438. PMID: 28810490, PMCID: PMC7162558, DOI: 10.1177/1359105317718615.
• The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administrationMesser LH, Forlenza GP, Wadwa RP, Weinzimer SA, Sherr JL, Hood KK, Buckingham BA, Slover RH, Maahs DM. The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration. Pediatric Diabetes 2017, 19: 14-17. PMID: 28656656, DOI: 10.1111/pedi.12535.
• 014–Pivotal Trial of a Hybrid-Closed Loop System in Type 1 DabetesBurkett L, Lee S, Shin J, Kaufman F, Buckingham B, Slover R, Weinzimer S. 014–Pivotal Trial of a Hybrid-Closed Loop System in Type 1 Dabetes. Journal Of Pediatric Nursing 2017, 34: 106. DOI: 10.1016/j.pedn.2017.02.023.
• Abstract #249: The Variability in Nighttime Insulin Delivery and Glucose Levels with a Hybrid Closed-Loop System in a Pivotal TrialLee S, Bailey T, Brazg R, Slover R, Ilany J, Bode B, Garg S, Buckingham B, Anderson S, Weinzimer S, Bergenstal R, Tamborlane W, Roy A, Cordero T, Huang S, Shin J, Kaufman F. Abstract #249: The Variability in Nighttime Insulin Delivery and Glucose Levels with a Hybrid Closed-Loop System in a Pivotal Trial. Endocrine Practice 2017, 23: 56-57. DOI: 10.1016/s1530-891x(20)44369-1.
• Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop SystemIturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Science Of Diabetes Self-Management And Care 2017, 43: 223-232. PMID: 28340542, PMCID: PMC7162535, DOI: 10.1177/0145721717697244.
• Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 DiabetesGarg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.
• Future Drug Treatments for Type 1 DiabetesSherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes. 2016, 985-999. DOI: 10.1002/9781118924853.ch66.
• Altered Integration of Structural Covariance Networks in Young Children With Type 1 DiabetesHosseini SM, Mazaika P, Mauras N, Buckingham B, Weinzimer SA, Tsalikian E, White NH, Reiss AL, Network F. Altered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes. Human Brain Mapping 2016, 37: 4034-4046. PMID: 27339089, PMCID: PMC5053865, DOI: 10.1002/hbm.23293.
• Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesBergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA 2016, 316: 1407-1408. PMID: 27629148, DOI: 10.1001/jama.2016.11708.
• Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 DiabetesSaggar M, Tsalikian E, Mauras N, Mazaika P, White NH, Weinzimer S, Buckingham B, Hershey T, Reiss AL. Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes. Diabetes 2016, 66: 754-762. PMID: 27702833, PMCID: PMC5319714, DOI: 10.2337/db16-0414.
• Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus ReportMaahs DM, Buckingham BA, Castle JR, Cinar A, Damiano ER, Dassau E, DeVries JH, Doyle FJ, Griffen SC, Haidar A, Heinemann L, Hovorka R, Jones TW, Kollman C, Kovatchev B, Levy BL, Nimri R, O’Neal D, Philip M, Renard E, Russell SJ, Weinzimer SA, Zisser H, Lum JW. Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care 2016, 39: 1175-1179. PMID: 27330126, PMCID: PMC4915553, DOI: 10.2337/dc15-2716.
• Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performanceLy TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes 2016, 18: 348-355. PMID: 27191182, DOI: 10.1111/pedi.12399.
• Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and LiraglutideSherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.
• Variations in Brain Volume and Growth in Young Children With Type 1 DiabetesMazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, Wilson DM, Tansey MJ, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL. Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes 2015, 65: 476-485. PMID: 26512024, PMCID: PMC4747456, DOI: 10.2337/db15-1242.
• Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With HyperglycemiaMauras N, Mazaika P, Buckingham B, Weinzimer S, White NH, Tsalikian E, Hershey T, Cato A, Cheng P, Kollman C, Beck RW, Ruedy K, Aye T, Fox L, Arbelaez AM, Wilson D, Tansey M, Tamborlane W, Peng D, Marzelli M, Winer KK, Reiss AL. Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia. Diabetes 2014, 64: 1770-1779. PMID: 25488901, PMCID: PMC4407847, DOI: 10.2337/db14-1445.
• Skin and Adhesive Issues With Continuous Glucose MonitorsEnglert K, Ruedy K, Coffey J, Caswell K, Steffen A, Levandoski L, Tsalikian E, Tansey M, Coffey J, Cabbage J, Salamati S, Mauras N, Fox L, Englert K, Permuy J, Sikes K, Buckingham B, Wilson D, Clinton P, Caswell K, Weinzimer S, Tamborlane W, Sherr J, Steffen A, Weyman K, Zgorski M, Tichy E, White N, Arbelaez A, Levandoski L, Starnes A, Beck R, Ruedy K, Kollman C, Xing D, Hall C, Stevens B, Grave G, Winer K, Leschek E, Becker D, Cleary P, Greenbaum C, Moran A, Steffes M, Bucksa J, Nowicki M, Makky V. Skin and Adhesive Issues With Continuous Glucose Monitors. Journal Of Diabetes Science And Technology 2014, 8: 745-751. PMID: 24876416, PMCID: PMC4764227, DOI: 10.1177/1932296814529893.
• Alterations in White Matter Structure in Young Children With Type 1 DiabetesBarnea-Goraly N, Raman M, Mazaika P, Marzelli M, Hershey T, Weinzimer SA, Aye T, Buckingham B, Mauras N, White NH, Fox LA, Tansey M, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL, . Alterations in White Matter Structure in Young Children With Type 1 Diabetes. Diabetes Care 2014, 37: 332-340. PMID: 24319123, PMCID: PMC3898758, DOI: 10.2337/dc13-1388.
• CHAPTER 19 Diabetes mellitusSperling M, Tamborlane W, Battelino T, Weinzimer S, Phillip M. CHAPTER 19 Diabetes mellitus. 2014, 846-900.e1. DOI: 10.1016/b978-1-4557-4858-7.00028-7.
• Neuroanatomical Correlates of Dysglycemia in Young Children With Type 1 DiabetesMarzelli MJ, Mazaika PK, Barnea-Goraly N, Hershey T, Tsalikian E, Tamborlane W, Mauras N, White NH, Buckingham B, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL, Network F. Neuroanatomical Correlates of Dysglycemia in Young Children With Type 1 Diabetes. Diabetes 2013, 63: 343-353. PMID: 24170697, PMCID: PMC3868050, DOI: 10.2337/db13-0179.
• The Impact of Insulin Pharmacokinetics and Pharmacodynamics on the Closed-loop Artificial PancreasLee J, Dassau E, Zisser H, Tamborlane W, Weinzimer S, Doyle F. The Impact of Insulin Pharmacokinetics and Pharmacodynamics on the Closed-loop Artificial Pancreas. 2013, 127-132. DOI: 10.1109/cdc.2013.6759870.
• Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 DiabetesSherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA. Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. Diabetes Care 2013, 36: 2909-2914. PMID: 23757427, PMCID: PMC3781513, DOI: 10.2337/dc13-0010.
• Effectiveness of a Spanish Language Clinic for Hispanic Youth with Type 1 DiabetesPalau-Collazo MM, Rose P, Sikes K, Kim G, Benavides V, Urban A, Weinzimer S, Tamborlane W. Effectiveness of a Spanish Language Clinic for Hispanic Youth with Type 1 Diabetes. Endocrine Practice 2013, 19: 800-804. PMID: 23757616, DOI: 10.4158/ep13004.or.
• The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*Buckingham B, Beck R, Ruedy K, Cheng P, Kollman C, Weinzimer S, DiMeglio L, Bremer A, Slover R, Cantwell M. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*. Diabetes Technology & Therapeutics 2013, 15: 401-408. PMID: 23570538, PMCID: PMC3643224, DOI: 10.1089/dia.2013.0002.
• Interstitial fluid glucose time-lag correction for real-time continuous glucose monitoringKeenan D, Mastrototaro J, Weinzimer S, Steil G. Interstitial fluid glucose time-lag correction for real-time continuous glucose monitoring. Biomedical Signal Processing And Control 2013, 8: 81-89. DOI: 10.1016/j.bspc.2012.05.007.
• Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes.Kanderian SS, Weinzimer S, Voskanyan G, Steil GM. Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes. Journal Of Diabetes Science And Technology 2009, 3: 1047-57. PMID: 20144418, PMCID: PMC2769900, DOI: 10.1177/193229680900300508.
• Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 DiabetesTsalikian E, Tamborlane W, Xing D, Becker D, Mauras N, Fiallo-Scharer R, Buckingham B, Weinzimer S, Steffes M, Singh R, Beck R, Ruedy K, Kollman C. Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1954-1959. PMID: 19675205, PMCID: PMC2768200, DOI: 10.2337/dc08-2298.
• Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 DiabetesBode B, Beck R, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy K, Tamborlane W, Weinzimer S, Wolpert H. Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2009, 32: 2047-2049. PMID: 19675193, PMCID: PMC2768224, DOI: 10.2337/dc09-0846.
• The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 DiabetesBeck R, Hirsch I, Laffel L, Tamborlane W, Bode B, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Huang E, Kollman C, Kowalski A, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1378-1383. PMID: 19429875, PMCID: PMC2713649, DOI: 10.2337/dc09-0108.
• Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple‐daily injection therapyWeinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple‐daily injection therapy. Pediatric Diabetes 2008, 10: 91-96. PMID: 19175899, DOI: 10.1111/j.1399-5448.2008.00476.x.
• Continuous Glucose Monitoring and Intensive Treatment of Type 1 DiabetesTamborlane W, Beck R, Bode B, Buckingham B, Chase H, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Hirsch I, Huang E, Kollman C, Kowalski A, Laffel L, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal Of Medicine 2008, 359: 1464-1476. PMID: 18779236, DOI: 10.1056/nejmoa0805017.
• Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial PancreasWeinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Diabetes Care 2008, 31: 934-939. PMID: 18252903, DOI: 10.2337/dc07-1967.
• CHAPTER 10 Diabetes MellitusSPERLING M, WEINZIMER S, TAMBORLANE W. CHAPTER 10 Diabetes Mellitus. 2008, 374-421. DOI: 10.1016/b978-141604090-3.50015-6.
• Hypoglycemia in childhood type 1 diabetes mellitus: Understanding and managing the dark side of intensive insulin therapyTamborlane W, Swan K, Weinzimer S. Hypoglycemia in childhood type 1 diabetes mellitus: Understanding and managing the dark side of intensive insulin therapy. Insulin 2007, 2: 157-165. DOI: 10.1016/s1557-0843(07)80059-5.
• Continuous Glucose Monitoring in Children with Type 1 DiabetesBuckingham B, Beck R, Tamborlane W, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy K, Tansey M, Weinzimer S, Wysocki T. Continuous Glucose Monitoring in Children with Type 1 Diabetes. The Journal Of Pediatrics 2007, 151: 388-393.e2. PMID: 17889075, PMCID: PMC2045068, DOI: 10.1016/j.jpeds.2007.03.047.
• Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal InsulinTsalikian E, Kollman C, Tamborlane W, Beck R, Fiallo-Scharer R, Fox L, Janz K, Ruedy K, Wilson D, Xing D, Weinzimer S. Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin. Diabetes Care 2006, 29: 2200-2204. PMID: 17003293, PMCID: PMC1584283, DOI: 10.2337/dc06-0495.
• Should continuous glucose monitors be used routinely in pediatric patients?Weinzimer S, Wilson D. Should continuous glucose monitors be used routinely in pediatric patients? Family Practice News 2006, 36: 8. DOI: 10.1016/s0300-7073(06)73924-x.
• Should continuous glucose monitors be used routinely in adolescent patients?WEINZIMER S, WILSON D. Should continuous glucose monitors be used routinely in adolescent patients? Internal Medicine News 2006, 39: 9. DOI: 10.1016/s1097-8690(06)74256-1.
• Evaluation of factors affecting CGMS calibration.Buckingham B, Kollman C, Beck R, Kalajian A, Fiallo-Scharer R, Tansey M, Fox L, Wilson D, Weinzimer S, Ruedy K, Tamborlane W. Evaluation of factors affecting CGMS calibration. Diabetes Technology & Therapeutics 2006, 8: 318-25. PMID: 16800753, PMCID: PMC1483845, DOI: 10.1089/dia.2006.8.318.
• Chapter 37 Diabetes Mellitus in Children and AdolescentsWeinzimer S, Tamborlane W. Chapter 37 Diabetes Mellitus in Children and Adolescents. 2006, 505-521. DOI: 10.1016/b978-1-4160-0273-4.50042-4.
• Analysis: How to Inspect When She's Expecting: Use of Continuous Glucose Monitoring in Diabetes During PregnancyWeinzimer S. Analysis: How to Inspect When She's Expecting: Use of Continuous Glucose Monitoring in Diabetes During Pregnancy. Diabetes Technology & Therapeutics 2005, 7: 707-709. DOI: 10.1089/dia.2005.7.707.
• CHAPTER 1 Type 1 Diabetes Mellitus in ChildrenWEINZIMER S, MAGGE S. CHAPTER 1 Type 1 Diabetes Mellitus in Children. 2005, 3-18. DOI: 10.1016/b978-0-323-01825-8.50030-2.
• CHAPTER 2 Type 2 Diabetes Mellitus in Children and AdolescentsHALE D, WEINZIMER S. CHAPTER 2 Type 2 Diabetes Mellitus in Children and Adolescents. 2005, 19-35. DOI: 10.1016/b978-0-323-01825-8.50031-4.
• Rediscovery of insulin pump treatment of childhood type 1 diabetes.Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95: 85-92. PMID: 15272243.
• Diabetes Mellitus in Children and AdolescentsWeinzimer S, Tamborlane W. Diabetes Mellitus in Children and Adolescents. 2004 DOI: 10.1002/0470862092.d0809.
• Management of Endocrine Dysfunction Following Brain Tumor TreatmentWeinzimer S, Moshang Jr. T. Management of Endocrine Dysfunction Following Brain Tumor Treatment. 2003, 0: 173-188. DOI: 10.1385/1-59259-336-4:173.
• Body composition and metabolic factors in obese children and adolescentsTershakovec AM, Kuppler KM, Zemel BS, Katz L, Weinzimer S, Harty MP, Stallings VA. Body composition and metabolic factors in obese children and adolescents. International Journal Of Obesity 2003, 27: 19-24. PMID: 12532149, DOI: 10.1038/sj.ijo.0802185.
• Biological significance of insulin-like growth factor binding proteinsWeinzimer S, Cohen P. Biological significance of insulin-like growth factor binding proteins. 2002, 2: 37-65. DOI: 10.1016/s1567-7443(02)80007-2.
• Acarbose treatment of postprandial hypoglycemia in children after Nissen fundoplicationNg D, Ferry R, Kelly A, Weinzimer S, Stanley C, Katz L. Acarbose treatment of postprandial hypoglycemia in children after Nissen fundoplication. The Journal Of Pediatrics 2001, 139: 877-879. PMID: 11743518, DOI: 10.1067/mpd.2001.119169.
• Graves' disease in patients with 22q11.2 deletionKawame H, Adachi M, Tachibana K, Kurosawa K, Ito F, Gleason M, Weinzimer S, Levitt-Katz L, Sullivan K, McDonald-McGinn D. Graves' disease in patients with 22q11.2 deletion. The Journal Of Pediatrics 2001, 139: 892-895. PMID: 11743521, DOI: 10.1067/mpd.2001.119448.
• Blue BallsRockney R, Alario A, Weinzimer S, Thornton P, Chalett J, Nerenberg L. Blue Balls. Pediatrics 2001, 108: 1233-1234. PMID: 11694711, DOI: 10.1542/peds.108.5.1233.
• Transferrin is an insulin-like growth factor-binding protein-3 binding protein.Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. The Journal Of Clinical Endocrinology & Metabolism 2001, 86: 1806-13. PMID: 11297622, DOI: 10.1210/jcem.86.4.7380.
• Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding ProteinWeinzimer S, Gibson T, Collett-Solberg P, Khare A, Liu B, Cohen P. Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding Protein. The Journal Of Clinical Endocrinology & Metabolism 2001, 86: 1806-1813. DOI: 10.1210/jcem.86.4.7380.
• Endocrine aspects of the 22q11.2 deletion syndromeWeinzimer S. Endocrine aspects of the 22q11.2 deletion syndrome. Genetics In Medicine 2001, 3: 19-22. PMID: 11339371, DOI: 10.1097/00125817-200101000-00005.
• Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-α Regulate Transcriptional Signaling and Apoptosis*Liu B, Lee H, Weinzimer S, Powell D, Clifford J, Kurie J, Cohen P. Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-α Regulate Transcriptional Signaling and Apoptosis*. Journal Of Biological Chemistry 2000, 275: 33607-33613. PMID: 10874028, DOI: 10.1074/jbc.m002547200.
• Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3Mannhardt B, Weinzimer S, Wagner M, Fiedler M, Cohen P, Jansen-Dürr P, Zwerschke W. Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3. Molecular And Cellular Biology 2000, 20: 6483-6495. PMID: 10938125, PMCID: PMC86123, DOI: 10.1128/mcb.20.17.6483-6495.2000.
• Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3Mannhardt B, Weinzimer S, Wagner M, Fiedler M, Cohen P, Jansen-Dürr P, Zwerschke W. Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3. Molecular And Cellular Biology 2000, 20: 6483-6495. DOI: 10.1128/.20.17.6483-6495.2000.
• Serum IGF‐I and IGFBP‐3 concentrations do not accurately predict growth hormone deficiency in children with brain tumoursWeinzimer S, Homan S, Ferry R, Moshang T. Serum IGF‐I and IGFBP‐3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours. Clinical Endocrinology 1999, 51: 339-345. PMID: 10469014, DOI: 10.1046/j.1365-2265.1999.00804.x.
• Cellular Actions of Insulin-Like Growth Factor Binding ProteinsFerry R, Katz L, Grimberg A, Cohen P, Weinzimer S. Cellular Actions of Insulin-Like Growth Factor Binding Proteins. Hormone And Metabolic Research 1999, 31: 192-202. PMID: 10226802, PMCID: PMC4151550, DOI: 10.1055/s-2007-978719.
• The IGF Axis in the Male Reproductive SystemWeinzimer S, Cohen P. The IGF Axis in the Male Reproductive System. 1999, 407-423. DOI: 10.1007/978-1-59259-712-3_18.
• ReplyWeinzimer S, Stanley C. Reply. The Journal Of Pediatrics 1998, 133: 801. PMID: 9842051, DOI: 10.1016/s0022-3476(98)70159-3.
• ReplyWeinzimer S, Stanley C. Reply. The Journal Of Pediatrics 1998, 133: 169. DOI: 10.1016/s0022-3476(98)70207-0.
• Growth Hormone Deficiency in Patients With a 22q11.2 Deletion: Expanding the PhenotypeWeinzimer S, McDonald-McGinn D, Driscoll D, Emanuel B, Zackai E, Moshang T. Growth Hormone Deficiency in Patients With a 22q11.2 Deletion: Expanding the Phenotype. Pediatrics 1998, 101: 929-932. PMID: 9565428, DOI: 10.1542/peds.101.5.929.
• Variability of Low IGF-I and IGFBP-3 Levels in Predicting Growth Hormone Deficiency in Children with Brain Tumors † 497Weinzimer S, Ferry R, Homan S, Moshang T. Variability of Low IGF-I and IGFBP-3 Levels in Predicting Growth Hormone Deficiency in Children with Brain Tumors † 497. Pediatric Research 1998, 43: 87-87. DOI: 10.1203/00006450-199804001-00518.
• Diabetes and transport: A potentially bittersweet combinationWOODWARD G, LEVY R, WEINZIMER S. Diabetes and transport: A potentially bittersweet combination. Pediatric Emergency Care 1998, 14: 71-76. PMID: 9516638, DOI: 10.1097/00006565-199802000-00019.
• A syndrome of congenital hyperinsulinism and hyperammonemiaWeinzimer S, Stanley C, Berry G, Yudkoff M, Tuchman M, Thornton P. A syndrome of congenital hyperinsulinism and hyperammonemia. The Journal Of Pediatrics 1997, 130: 661-664. PMID: 9108870, DOI: 10.1016/s0022-3476(97)70256-7.
• The 22q11.2 Deletion: Screening, Diagnostic Workup, and Outcome of Results; Report on 181 PatientsMcDonald-McGinn DM, LaRossa D, Goldmuntz E, Sullivan K, Eicher P, Gerdes M, Moss E, Wang P, Solot C, Schultz P, Lynch D, Bingham P, Keenan G, Weinzimer S, Ming JE, Driscoll D, Clark BJ, Markowitz R, Cohen A, Moshang T, Pasquariello P, Randall P, Emanuel BS, Zackai EH. The 22q11.2 Deletion: Screening, Diagnostic Workup, and Outcome of Results; Report on 181 Patients. Genetic Testing And Molecular Biomarkers 1997, 1: 99-108. PMID: 10464633, DOI: 10.1089/gte.1997.1.99.
• USE OF A SENSITIVE ASSAY TO DOCUMENT ELEVATED INSULIN LEVELS IN CONGENITAL HYPERINSULINISM. † 575Satin-Smith M, Katz L, Drott H, Collett-Solberg P, Weinzimer S, Thornton P, Baker L, Stanley C. USE OF A SENSITIVE ASSAY TO DOCUMENT ELEVATED INSULIN LEVELS IN CONGENITAL HYPERINSULINISM. † 575. Pediatric Research 1996, 39: 98-98. DOI: 10.1203/00006450-199604001-00596.
• GROWTH HORMONE DEFICIENCY IN THE 22Q11 DELETION SYNDROME: A REPORT OF THREE CASES. † 881Weinzimer S, McDonald-McGinn D, Zackai E, Moshang T. GROWTH HORMONE DEFICIENCY IN THE 22Q11 DELETION SYNDROME: A REPORT OF THREE CASES. † 881. Pediatric Research 1996, 39: 149-149. DOI: 10.1203/00006450-199604001-00903.
• HYPERINSULINISM AND HYPERAMMONEMIA: A DISTINCT GENETIC SYNDROME.† 882Weinzimer S, Yudkoff M, Thornton P, Stanley C. HYPERINSULINISM AND HYPERAMMONEMIA: A DISTINCT GENETIC SYNDROME.† 882. Pediatric Research 1996, 39: 149-149. DOI: 10.1203/00006450-199604001-00904.